Intravenous Colchicine for Treatment of Patients with Familial Mediterranean Fever Unresponsive to Oral Colchicine

Journal of Rheumatology

Volumn 30, Issue 12, 2003, Pages 2620-2623

  Lidar, Merav ^a   Kedem, Ron ^a   Langevitz, Pnina ^a   Pras, Mordechai ^a   Livneh, Avi ^a,b  

^a Department of Medicine ^*  (Israel)

^b HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

Author keywords

Colchicine; Colchicine treatment failure; Familial mediterranean fever

Indexed keywords

ANALGESIC AGENT; COLCHICINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMAN; MALE; PHLEBITIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; COLCHICINE; DRUG RESISTANCE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; RETREATMENT; TREATMENT OUTCOME;

EID: 0346848792     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause FMF. Cell 1997;90:797-807.
2. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25-31.
3. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967;43:227-53.
4. Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 1974;291:932-4.
5. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. New Engl J Med 1986;314:1001-5.
6. Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994;37:1804-11.
7. Pras M. FMF: past, present and future [abstract]. Clin Exp Rheumatol 2002;20 Suppl 26:66.
8. Livneh A, Langevitz P, Zemer D, et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum 1996;26:612-27.
9. Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol 2000;14:477-98.
10. Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann JM. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol 1994;46:351-4.
11. Lidar M, Scherrmann JM, Chetrit A, Niel E, Gershoni R, Livneh A. Clinical, genetic, pharmacokinetic and socioeconomical characterization of colchicine nonresponsiveness in FMF [abstract]. Clin Exp Rheumatol 2002;20 Suppl 26:88.
12. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1884-90.
13. Evans TI, Wheeler MT, Small RE, Breitbach SA, Sanders KM, Roberts WN. A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J Rheumatol 1996;23:143-8.
14. Maldonado MA, Salzman A, Varga J. Intravenous colchicine use in crystal induced arthropathies: A retrospective analysis of hospitalized patients. Clin Exp Rheumatol 1997;15:487-92.
15. Tunca M, Tankurt E, Akbaylar Akpinar H, et al. The efficacy of interferon alpha on colchicines-resistant familial Mediterranean fever attacks: A pilot study. Br J Rheumatol 1997;36:1005-8.